All In Biotech

Drug Trial Radar · NCT05417789

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Oct 9, 2024

Primary completion

Dec 23, 2025

Study completion Sep 30, 2030

Sponsor

Lead sponsor
SynOx Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. Part 2 is a long-term double-blind follow-up phase of the subjects on emactuzumab or placebo. Subjects assigned to placebo in Part 1 have the option, subject to eligibility, to crossover to receive open-label emactuzumab in Part 2. Subjects assigned to active drug in Part 1 have the option to receive open-label retreatment under certain circumstances.

Conditions

  • TGCT

Interventions

  • EmactuzumabDrug

    Emactuzumab administered once every 2 weeks (q2w)

  • PlaceboDrug

    Matching placebo administered once every 2 weeks (q2w)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Day 0 - Day 180 (6 months)

Locations

33 sites in 12 countries. Site status is shown where the registry gives one.

  • NextGen Oncology

    Beverly Hills, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • The Ohio State University

    Columbus, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • MedStar Washington Hospital Center

    Georgetown, Washington

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussels Capital, Belgium

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, Canada

  • UNICANCER - Centre Oscar Lambret

    Lille, France

  • Institut Curie - Hôpital de Paris

    Paris, France

  • Oncopole Claudius Regaud Oncologie Médicale

    Toulouse, France

  • Institut Bergonie - PPDS

    Bordeaux, Gironde, France

  • Institut de Cancerologie de Ouest - Saint Herblain

    Saint-Herblain, Loire-Atlantique, France

  • AP-HP - Hôpital Cochin - Port-Royal, site Cochin

    Paris, Paris, France

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, Rhône, France

  • IRCCS lstituto Ortopedico Rizzoli

    Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Lazio, Italy

  • Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena

    Rome, Lazio, Italy

  • Fondazione del Piemonte per l'Oncologia (IRCCS)

    Candiolo, Piedmont, Italy

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo, Sicily, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocio - PPDS

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Zaragoza, Zaragoza, Spain

  • Skanes Universitetssjukhus Lund

    Lund, Skåne County, Sweden

  • Universitäts Kinderspital Beider Basel (UKBB)

    Basel, Switzerland

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • St James's University Hospital

    Leeds, United Kingdom

  • University College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.